Predictors for therapeutic effect of Lusutrombopag in chronic liver disease

Predictors for therapeutic effect of Lusutrombopag in chronic liver disease - Predictors of Lusutrombopag

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025776

Enrollment

Registered

2017-01-20

Start date

2017-01-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic liver disease

Interventions

Multicenter, single-arm, open-label trial

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Platelet count<50*10^9/L in liver cirrhosis patient. 2.age >20 3.patients received a fully described on the basis of informed consent document

Exclusion criteria

Exclusion criteria: 1.Patients with a hematologic malignancy. 2.Active malignancy at time of study entry except HCC. 3.Patients who underwent liver transplantation 4.Patients with a severe liver dysfunction (Child-pugh C) 5.Patients with a medical history of thrombosis. 6.Patients with a medical history of thrombotic disease adult patients. 7.Women who are pregnant or breastfeeding 8.Severe GI bleeding. 9.Not appropriate for this study

Design outcomes

Primary

Measure	Time frame
Response rate (more than 50,000 /mm^3) at after adminstraion of lusutrombopag.	—

Secondary

Measure	Time frame
1.Increase rate of Platelet count. 2.Correlation with increase rate and thrombopoietin. 3.Correlation with increase rate and megakaryocyte. 4.Correlation with increase rate and portal hypertention. 5.Adverse event occurrence rate.	—

Countries

Japan

Contacts

Public ContactHaruki Uojima

Kitasato University School of Medicine Department of Gastroenterology

kiruha@kitasato-u.ac.jp042-778-8390

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026